Hepatic disorders associated with the use of Ivermectin for SARS-CoV-2 infection in adults: a pharmacovigilance study in VigiBase (2022)

Peer-Reviewed Study · Oscanoa TJ, Amado J, Romero-Ortuno R, Carvajal A · 2022

Oscanoa TJ et al., 2022: VigiBase analysis of ivermectin case safety reports to 7 March 2021: of 1,393 reports, 60 were serious and 25 involved COVID-19 use, with six hepatic disorders among the COVID-19 cases. It quantifies hepatic signals at population scale during the pandemic repurposing.

Among the latter, 6 experienced hepatic disorders (hepatitis, hepatocellular injury, cholestasis, increased alanine aminotransferase and/or aspartate aminotransferase levels, abnormal liver function tests).

Oscanoa TJ et al., 2022: VigiBase analysis of ivermectin case safety reports to 7 March 2021: of 1,393 reports, 60 were serious and 25 involved COVID-19 use, with six hepatic disorders among the COVID-19 cases. It quantifies hepatic signals at population scale during the pandemic repurposing. C5 pharmacovigilance. Study type: retrospective pharmacovigilance database study (WHO VigiBase individual case safety reports); N=1,393 ivermectin ICSRs reviewed, 60 serious, 25 COVID-19-related, 6 with hepatic disorders; countries: reports from more than 130 countries (Peru/Spain authors). Dose: not stated in the abstract. Comparator: none. Funder and declared conflicts: not in the PubMed record. Study type: uncontrolled series.